AVYXA HOLDINGS
SpecialtyAVYXA HOLDINGS is a specialty pharmaceutical company focused on Oncology, Gastroenterology. Key products include FRINDOVYX.
Key Drugs
Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.
Malignant Lymphoma
Methotrexate Toxicity
Breast Cancer
Ovarian Cancer
Actinic Keratosis
Recent FDA Approvals
New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.
Therapeutic Areas
Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.
Top Competitors
Companies with the most overlap in therapeutic areas and drug targets. Based on approved drugs and pipeline focus.
Pipeline Snapshot
Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • FRINDOVYX leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling